AAPL298.01+2.06 (+0.70%) ▲|ABBV216.49-4.74 (-2.14%) ▼|ABT88.41-0.09 (-0.10%) ▼|ACN127.98-28.03 (-17.97%) ▼|ADBE195.16-1.12 (-0.57%) ▼|AMAT617.11+24.19 (+4.08%) ▲|AMD537.37+24.89 (+4.86%) ▲|AMGN337.60-4.06 (-1.19%) ▼|AMT176.05-5.04 (-2.78%) ▼|AMZN244.39+6.89 (+2.90%) ▲|AVGO411.35+18.45 (+4.70%) ▲|AXP338.00-2.54 (-0.75%) ▼|BA222.72-2.91 (-1.29%) ▼|BAC56.20-0.33 (-0.58%) ▼|BKNG171.78+0.15 (+0.09%) ▲|BLK1,050.09-7.29 (-0.69%) ▼|BMY54.00-1.28 (-2.32%) ▼|BNY143.63-2.44 (-1.67%) ▼|BRK-B489.46-1.82 (-0.37%) ▼|C143.06-0.72 (-0.50%) ▼|CAT985.82+29.90 (+3.13%) ▲|CL89.48-1.10 (-1.21%) ▼|CMCSA22.43-0.26 (-1.15%) ▼|COF201.53+0.66 (+0.33%) ▲|COP107.74-3.47 (-3.12%) ▼|COST951.45-14.14 (-1.46%) ▼|CRM151.78-3.24 (-2.09%) ▼|CSCO119.54+2.21 (+1.88%) ▲|CVS98.32-0.84 (-0.85%) ▼|CVX173.63-3.95 (-2.22%) ▼|DE589.24+0.77 (+0.13%) ▲|DHR177.17-0.59 (-0.33%) ▼|DIS103.89+3.03 (+3.00%) ▲|DUK123.86+0.13 (+0.11%) ▲|EMR150.66+1.66 (+1.11%) ▲|FDX326.20+0.27 (+0.08%) ▲|GD350.01-12.82 (-3.53%) ▼|GE357.64+0.61 (+0.17%) ▲|GEV1,109.73+60.87 (+5.80%) ▲|GILD123.76-1.69 (-1.35%) ▼|GM79.29-0.29 (-0.36%) ▼|GOOG367.46+5.36 (+1.48%) ▲|GOOGL368.03+4.24 (+1.17%) ▲|GS1,096.56-2.58 (-0.23%) ▼|HD334.28+6.80 (+2.08%) ▲|HON229.01+0.40 (+0.18%) ▲|IBM249.10-13.25 (-5.05%) ▼|INTC133.99+12.89 (+10.64%) ▲|INTU267.00-2.08 (-0.77%) ▼|ISRG406.78+4.60 (+1.14%) ▲|JNJ228.39-5.81 (-2.48%) ▼|JPM325.22-8.24 (-2.47%) ▼|KO79.39-0.54 (-0.68%) ▼|LIN512.15-3.70 (-0.72%) ▼|LLY1,098.57-13.43 (-1.21%) ▼|LMT510.95-21.37 (-4.01%) ▼|LOW222.20+4.93 (+2.27%) ▲|LRCX389.04+14.86 (+3.97%) ▲|MA489.79-3.20 (-0.65%) ▼|MCD278.61-5.21 (-1.84%) ▼|MDLZ60.12-0.74 (-1.22%) ▼|MDT79.34+1.20 (+1.54%) ▲|META577.22+9.64 (+1.70%) ▲|MMM160.60+1.37 (+0.86%) ▲|MO69.12+0.17 (+0.25%) ▲|MRK113.87-1.57 (-1.36%) ▼|MS223.17-1.79 (-0.80%) ▼|MSFT379.40+0.49 (+0.13%) ▲|MU1,133.99+90.80 (+8.70%) ▲|NEE86.75+1.02 (+1.19%) ▲|NFLX77.38+0.42 (+0.55%) ▲|NKE45.20+1.01 (+2.29%) ▲|NOW95.04-0.44 (-0.46%) ▼|NVDA210.69+6.04 (+2.95%) ▲|ORCL184.29+0.76 (+0.41%) ▲|PEP142.02+0.43 (+0.30%) ▲|PFE25.21-0.71 (-2.74%) ▼|PG150.38-0.18 (-0.12%) ▼|PLTR128.47-2.16 (-1.65%) ▼|PM178.40-1.04 (-0.58%) ▼|QCOM226.11+13.14 (+6.17%) ▲|RTX185.60-6.98 (-3.62%) ▼|SBUX100.65+0.83 (+0.83%) ▲|SCHW91.70-2.81 (-2.97%) ▼|SO93.09+0.56 (+0.61%) ▲|SPG211.33+1.47 (+0.70%) ▲|T22.01-0.43 (-1.92%) ▼|TMO464.61+2.92 (+0.63%) ▲|TMUS181.67+0.36 (+0.20%) ▲|TSLA400.49+4.11 (+1.04%) ▲|TXN322.86+20.98 (+6.95%) ▲|UBER71.64+0.73 (+1.03%) ▲|UNH400.96+1.43 (+0.36%) ▲|UNP256.88-1.17 (-0.45%) ▼|UPS104.86-0.27 (-0.26%) ▼|USB58.14+0.23 (+0.40%) ▲|V327.24-3.14 (-0.95%) ▼|VZ45.37-0.47 (-1.03%) ▼|WFC82.20-1.61 (-1.92%) ▼|WMT117.18-0.95 (-0.80%) ▼|XOM137.81-2.93 (-2.08%) ▼|AAPL298.01+2.06 (+0.70%) ▲|ABBV216.49-4.74 (-2.14%) ▼|ABT88.41-0.09 (-0.10%) ▼|ACN127.98-28.03 (-17.97%) ▼|ADBE195.16-1.12 (-0.57%) ▼|AMAT617.11+24.19 (+4.08%) ▲|AMD537.37+24.89 (+4.86%) ▲|AMGN337.60-4.06 (-1.19%) ▼|AMT176.05-5.04 (-2.78%) ▼|AMZN244.39+6.89 (+2.90%) ▲|AVGO411.35+18.45 (+4.70%) ▲|AXP338.00-2.54 (-0.75%) ▼|BA222.72-2.91 (-1.29%) ▼|BAC56.20-0.33 (-0.58%) ▼|BKNG171.78+0.15 (+0.09%) ▲|BLK1,050.09-7.29 (-0.69%) ▼|BMY54.00-1.28 (-2.32%) ▼|BNY143.63-2.44 (-1.67%) ▼|BRK-B489.46-1.82 (-0.37%) ▼|C143.06-0.72 (-0.50%) ▼|CAT985.82+29.90 (+3.13%) ▲|CL89.48-1.10 (-1.21%) ▼|CMCSA22.43-0.26 (-1.15%) ▼|COF201.53+0.66 (+0.33%) ▲|COP107.74-3.47 (-3.12%) ▼|COST951.45-14.14 (-1.46%) ▼|CRM151.78-3.24 (-2.09%) ▼|CSCO119.54+2.21 (+1.88%) ▲|CVS98.32-0.84 (-0.85%) ▼|CVX173.63-3.95 (-2.22%) ▼|DE589.24+0.77 (+0.13%) ▲|DHR177.17-0.59 (-0.33%) ▼|DIS103.89+3.03 (+3.00%) ▲|DUK123.86+0.13 (+0.11%) ▲|EMR150.66+1.66 (+1.11%) ▲|FDX326.20+0.27 (+0.08%) ▲|GD350.01-12.82 (-3.53%) ▼|GE357.64+0.61 (+0.17%) ▲|GEV1,109.73+60.87 (+5.80%) ▲|GILD123.76-1.69 (-1.35%) ▼|GM79.29-0.29 (-0.36%) ▼|GOOG367.46+5.36 (+1.48%) ▲|GOOGL368.03+4.24 (+1.17%) ▲|GS1,096.56-2.58 (-0.23%) ▼|HD334.28+6.80 (+2.08%) ▲|HON229.01+0.40 (+0.18%) ▲|IBM249.10-13.25 (-5.05%) ▼|INTC133.99+12.89 (+10.64%) ▲|INTU267.00-2.08 (-0.77%) ▼|ISRG406.78+4.60 (+1.14%) ▲|JNJ228.39-5.81 (-2.48%) ▼|JPM325.22-8.24 (-2.47%) ▼|KO79.39-0.54 (-0.68%) ▼|LIN512.15-3.70 (-0.72%) ▼|LLY1,098.57-13.43 (-1.21%) ▼|LMT510.95-21.37 (-4.01%) ▼|LOW222.20+4.93 (+2.27%) ▲|LRCX389.04+14.86 (+3.97%) ▲|MA489.79-3.20 (-0.65%) ▼|MCD278.61-5.21 (-1.84%) ▼|MDLZ60.12-0.74 (-1.22%) ▼|MDT79.34+1.20 (+1.54%) ▲|META577.22+9.64 (+1.70%) ▲|MMM160.60+1.37 (+0.86%) ▲|MO69.12+0.17 (+0.25%) ▲|MRK113.87-1.57 (-1.36%) ▼|MS223.17-1.79 (-0.80%) ▼|MSFT379.40+0.49 (+0.13%) ▲|MU1,133.99+90.80 (+8.70%) ▲|NEE86.75+1.02 (+1.19%) ▲|NFLX77.38+0.42 (+0.55%) ▲|NKE45.20+1.01 (+2.29%) ▲|NOW95.04-0.44 (-0.46%) ▼|NVDA210.69+6.04 (+2.95%) ▲|ORCL184.29+0.76 (+0.41%) ▲|PEP142.02+0.43 (+0.30%) ▲|PFE25.21-0.71 (-2.74%) ▼|PG150.38-0.18 (-0.12%) ▼|PLTR128.47-2.16 (-1.65%) ▼|PM178.40-1.04 (-0.58%) ▼|QCOM226.11+13.14 (+6.17%) ▲|RTX185.60-6.98 (-3.62%) ▼|SBUX100.65+0.83 (+0.83%) ▲|SCHW91.70-2.81 (-2.97%) ▼|SO93.09+0.56 (+0.61%) ▲|SPG211.33+1.47 (+0.70%) ▲|T22.01-0.43 (-1.92%) ▼|TMO464.61+2.92 (+0.63%) ▲|TMUS181.67+0.36 (+0.20%) ▲|TSLA400.49+4.11 (+1.04%) ▲|TXN322.86+20.98 (+6.95%) ▲|UBER71.64+0.73 (+1.03%) ▲|UNH400.96+1.43 (+0.36%) ▲|UNP256.88-1.17 (-0.45%) ▼|UPS104.86-0.27 (-0.26%) ▼|USB58.14+0.23 (+0.40%) ▲|V327.24-3.14 (-0.95%) ▼|VZ45.37-0.47 (-1.03%) ▼|WFC82.20-1.61 (-1.92%) ▼|WMT117.18-0.95 (-0.80%) ▼|XOM137.81-2.93 (-2.08%) ▼|
23.4 C
New York
Saturday, June 20, 2026

Tag: small molecule

Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC

SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of...

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery...

Ratio Therapeutics Partners with Macrocyclics for Exclusive Manufacturing and Distribution of its Radiopharmaceutical Chelator Platform

BOSTON, June 13, 2025 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring,...

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration

CAMBRIDGE, Mass. and LIVERPOOL, United Kingdom, June 13, 2025 /PRNewswire/ -- XtalPi, a leading life sciences and new materials R&D platform powered by quantum...

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel...

Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS)...

Kelun-Biotech’s Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer

CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that the Company has received a clinical trial notice...

Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon’s Board of Directors

Noted pharmaceutical industry executive Frederick Beddingfield, MD, PhD, has joined the Neurodon Board of Directors, bringing years of industry leadership.

Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders

Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs

Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders

Strasbourg, France and Charleroi, Belgium, June 11th  2025 – Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic agents to treat depression and other neuropsychiatric condition, announced today that it has closed an oversubscribed EUR 11.25 million Seed funding round. The round was co-led by Kurma Partners, WE Life Sciences and the French Tech Seed fund managed on behalf of the French government by Bpifrance as part of France 2030, with participation from Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est and Sambrinvest. Elkedonia is bringing together stakeholders from across the European ecosystem, with headquarters in Strasbourg, France and an affiliate in Charleroi, Belgium.

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics

- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSmall molecule